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Interleukin-33 signaling exacerbates experimental infectious
colitis by enhancing gut permeability and inhibiting protective
Th17 immunity
Vittoria Palmieri1, Jana-Fabienne Ebel1, Nhi Ngo Thi Phuong1, Robert Klopfleisch2, Vivian Pham Vu3,4, Alexandra Adamczyk1,
Julia Zöller1, Christian Riedel5, Jan Buer1, Philippe Krebs3, Wiebke Hansen1, Eva Pastille1 and Astrid M. Westendorf 1
A wide range of microbial pathogens is capable of entering the gastrointestinal tract, causing infectious diarrhea and colitis. A finely
tuned balance between different cytokines is necessary to eradicate the microbial threat and to avoid infection complications. The
current study identified IL-33 as a critical regulator of the immune response to the enteric pathogen Citrobacter rodentium. We
observed that deficiency of the IL-33 signaling pathway attenuates bacterial-induced colitis. Conversely, boosting this pathway
strongly aggravates the inflammatory response and makes the mice prone to systemic infection. Mechanistically, IL-33 mediates its
detrimental effect by enhancing gut permeability and by limiting the induction of protective T helper 17 cells at the site of
infection, thus impairing host defense mechanisms against the enteric pathogen. Importantly, IL-33-treated infected mice
supplemented with IL-17A are able to resist the otherwise strong systemic spreading of the pathogen. These findings reveal a novel
IL-33/IL-17A crosstalk that controls the pathogenesis of Citrobacter rodentium-driven infectious colitis. Manipulating the dynamics of
cytokines may offer new therapeutic strategies to treat specific intestinal infections.
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INTRODUCTION
Infectious diarrhea and colitis due to pathogenic intestinal bacteria
represent a major health problem in both developing and
developed countries1. Consequently, a thorough understanding of
the infectious process and the underlying immunological responses
is required for the identification and treatment of these infectious
diseases. Citrobacter rodentium (CR) is a non-invasive attaching/
effacing enteric pathogen, which infects intestinal epithelial cells
(IECs) and causes infectious colitis in mice2. Thus, it is routinely used
to mimic human pathogenic Escherichia coli infections and to study
host-pathogen interactions. Similar to other enteropathogens, CR
elicits a strong Th1 and Th17 immune response in the colon, which
is important for the clearance of infection3. Th1 cells produce
interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), promoting
macrophage and cytotoxic T cell activation. Th17 cells are induced
by IL-1β, IL-6, transforming growth factor-β, and release IL-17A, IL-
17F, and IL-22, which are crucial for the host defense and bacterial
clearance by inducing the production of antimicrobial peptides and
fostering the maintenance of intestinal barrier functions4. While an
appropriate cytokine release is required to mount an effective
immune response against microbial pathogens, excessive produc-
tion of some cytokines can sustain the inflammatory process and
increase the risk of infection complications.
IL-33, a member of the IL-1 cytokine family5, has become of
great interest in the field of intestinal inflammation. IL-33 is
constitutively expressed at high levels in epithelial barrier tissues
such as the intestine, and is primarily secreted by fibroblasts,
epithelial cells, and endothelial cells in response to injury6. Upon
release, IL-33 binds to the receptor ST2, which exists in two forms
as splice variants: a soluble form (sST2), which acts as a decoy
receptor, sequesters free IL-33, and does not signal, and a
membrane-bound form (ST2), which activates the MyD88/NF-κB
signaling pathway to modulate immune cell functions7. Several
immune cells, from both the innate and adaptive lineages, are
targets of IL-33 as they express the membrane-bound receptor
ST2 either constitutively or transiently8. Besides immune cells, IL-
33 was also shown to target intestinal epithelial progenitors as
these cells functionally express ST29. Depending on the physio-
logical context, IL-33 has been described to be host-protective or
-pathogenic in the gut10. Studies using colitis mouse models have
shown that administration of recombinant IL-33 ameliorates
intestinal inflammation11,12. Furthermore, IL-33−/− mice showed
higher susceptibility to infection and severe gut tissue destruction
in a model of Salmonellosis9. In contrast, during chronic colitis
IL-33 was recognized to be detrimental by favoring a tumor-
promoting immune environment13. Taken together, the precise
role of the IL-33/ST2 signaling pathway in the intestine is still
ambiguous and must be carefully analyzed with respect to the
inflammatory state, the infectious agent, and the specific host
immune response involved.
In the present study, we identified that deficiency of the IL-33/
ST2 signaling pathway attenuates CR-associated colon pathology.
Conversely, boosting this pathway strongly aggravates bacteria-
driven colitis and contributes to systemic pathogen dissemination
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by mitigating the intestinal epithelial integrity. In addition, we
identified IL-33 as a negative regulator of Th17 cell differentiation,
cells that are essential for the clearance of the pathogen. In
summary, our findings reveal the need of a tightly regulated
balance between IL-17A and IL-33-mediated signals for the
clearance of specific enteric bacterial pathogens and the control
of infection-driven intestinal immunopathology.
RESULTS
Enhanced colonic ST2 expression following C. rodentium infection
IL-33 and its transmembrane receptor ST2 have been described as
important players in the maintenance of gut homeostasis14. To
determine whether the expression of ST2 and IL-33 is altered
during CR infection, wild-type (WT) C57BL/6 mice were infected
with CR and analyzed at different time points after infection
(Fig. 1a). Bacterial-induced colitis was confirmed on day 10 after
infection by colonic histopathological analysis (Fig. 1b). Remark-
ably, we detected a significant upregulation of the membrane-
bound isoform of ST2 (St2) at mRNA levels in the colons of
infected mice compared to non-infected animals on day 10 after
infection (Fig. 1c), but no significant alterations in the soluble form
(sST2) in the serum (Fig. 1d). Interestingly, IL-33 was highly
abundant in the colon under steady-state, and Il33 transcripts and
IL-33 protein were slightly but not significantly increased at day 10
post infection (Fig. 1e). Conversely, IL-17A, TNF-α, and IFN-γ
secretion were strongly induced in the colon of CR-infected mice
compared to non-infected mice at day 10 of infection (Fig. 1f).
Taken together, these data suggest that IL-33/ST2 signaling is
controlled by the expression of the transmembrane receptor ST2
rather than via the modulation of IL-33 levels during enteric
infection with CR.
Lack of IL-33/ST2 signaling ameliorates C. rodentium-induced
colitis
To address the physiological function of IL-33/ST2 signaling during
intestinal bacterial infection, we first infected wild-type controls (WT)
and ST2 knockout mice (St2−/−) as well as IL-33 knockout mice
(Il33−/−) with CR for 10 days. Whereas CR-infected WT mice showed
reduced body weight in comparison to non-infected WT controls at
day 10, no differences in the body weight were observed between
infected and non-infected knockout mice (Fig. 2a and c). Well in line,
colon damage and inflammation (histopathological score)
were significantly reduced in CR-infected St2−/− compared to WT
mice (Fig. 2b). Likewise, Il33−/− mice displayed less pathological
alterations in the infected colon (Fig. 2d). Collectively, these data
provide evidence that the IL-33/ST2 axis contributes to CR-induced
pathogenesis.
IL-33 administration aggravates C. rodentium infection
Next, we assessed whether the host response to CR infection is
altered by further boosting ST2 signaling. Thus, CR-infected and
naïve mice were treated with IL-33 on the day of infection and
every second day for the duration of the experiment (Fig. 3a).
IL-33-treated CR-infected mice showed a dramatic loss of body
weight from day 5 on compared to PBS-treated infected mice,
with up to 20% reduction at day 8 of infection (Fig. 3b). These
mice also suffered from severe diarrhea, mild rectal bleeding and
strongly enhanced intestinal CR burden compared to PBS-treated
CR-infected controls (Fig. 3c). Moreover, IL-33-treated infected
animals showed shorter colons (Fig. 3d) and more severe colon
pathology with extensive mucosal defects and inflammatory cell
infiltration into the lamina propria in comparison to infected
controls (Fig. 3e). Importantly, we observed no signs of intestinal
inflammation when IL-33 was administered to non-infected mice.
Nevertheless, in accordance with previous studies15, colon
tissues from non-infected mice subjected to IL-33 treatment
revealed mild hyperplasia (Fig. 3e). Given the enhanced CR
burden in the feces of IL-33-treated infected mice, we checked
whether IL-33 treatment interferes with the production of
antimicrobial peptides that have been shown to contribute to
the clearance of CR16. Reg3γ expression was strongly induced in
the colon of CR-infected mice in comparison to non-infected
controls. In contrast, mice treated with IL-33 during infection
showed a substantial reduction in Reg3γ expression (Fig. 3f). CR
infection is normally restricted to the distal colon in C57BL/6 WT
mice17. Interestingly, we observed strongly enhanced bacterial
loads in the blood, liver and spleen of IL-33-treated CR-infected
mice but not in PBS-treated infected animals (Fig. 3g), indicating
bacterial translocation to systemic compartments. Moreover,
serum levels of IL-6, TNFα and IL-10 were strongly increased
in CR-infected animals that had received IL-33 (Fig. 3h).
Collectively, these findings suggest that IL-33 promotes the
intestinal immunopathology associated with CR and the systemic
dissemination of the enteric pathogen.
ST2 is mainly expressed by colonic Tregs during C. rodentium
infection
IL-33 triggers multiple functions in several ST2-expressing cells14.
To identify the immune cells that potentially react to IL-33 to
cause the severe phenotype observed in our model, we next
determined which ST2+ immune cells changed in frequency and
number upon CR infection. ST2+ macrophages, DCs and ILCs were
found at very low percentages and numbers in the colonic
lamina propria at steady-state and during CR infection. Among T
lymphocytes, CD4+ T cells represented the highest proportion of
ST2+ cells, with a tendency to increase in the colon of CR-infected
mice, which was in particular the case for Foxp3+CD4+ regulatory
T cells (Tregs) (Fig. 4a, b). Thus, we first focused our analysis on this
regulatory T cell subset.
The detrimental effect of IL-33 is independent of ST2-expressing
Treg expansion
IL-33 has been described to expand Tregs and sustain their
suppressive functions under inflammatory conditions18. Moreover,
enhanced Treg frequencies are often associated with reduced T
cell effector function during infection, which can lead to
diminished pathogen clearance and severe pathogen-induced
inflammation19. In agreement with these previous reports, IL-33
treatment increased the frequencies of CD4+Foxp3+ Tregs and
particularly of ST2+CD4+Foxp3+ Tregs in both CR-infected and
non-infected mice (Fig. 5a and Supplementary Fig. 1a). To
determine whether the increased frequencies of ST2+ Tregs in
IL-33-treated animals accounted for the severe course of disease
in CR-infected mice, we performed infection experiments with and
without IL-33 treatment of ST2flox/flox x FIC-Cre mice (ST2fl/fl/FIC), in
which ST2 is ablated specifically in Foxp3+ Tregs (Fig. 5b).
Surprisingly, no significant differences were observed in body
weight loss, colon length and immunopathology, when either ST2-
sufficient (FIC) or ST2-deficient Treg (ST2fl/fl/FIC) infected animals
were treated with IL-33 (Fig. 5c–e). More importantly, both groups
showed comparable systemic bacterial dissemination upon IL-33
application (Fig. 5f). Thus, the specific accumulation of ST2-
expressing Tregs induced by IL-33 is not responsible for the
uncontrolled pathogen dissemination and severe disease progres-
sion during CR infection. To determine the overall impact of Tregs
on the outcome of CR infection in the presence of IL-33, we next
used DEREG mice in our model, which allow the specific depletion
of all Foxp3+ Tregs by diphtheria toxin application (Supplemen-
tary Fig. 1b). In line with the phenotype seen in ST2fl/fl/FIC mice,
both Treg-sufficient and Treg-depleted CR-infected mice treated
with IL-33 showed similar high susceptibility to CR infection
(Supplementary Fig. 1c–e). In summary, Tregs seem not to drive
the enhanced pathology induced by IL-33 during CR infection.
Consequently, other cell types targeted by IL-33 must be
responsible for the harmful course of CR-driven colitis.
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IL-33 dampens IL-17A expression during C. rodentium infection
and interferes with Th17 cell differentiation
Intestinal infection with CR requires the accumulation of IL-17A-
producing cells to clear the pathogen20. Strikingly, IL17A
expression was markedly enhanced in CR-infected mice but not
in infected mice that were treated with IL-33 (Fig. 6a). To address
whether IL-33/ST2 signaling may negatively influence Th17 cell
induction within the infected colon, we measured the frequencies
of IL-17A+Foxp3-CD4+ T cells in colonic tissues as displayed in
Fig. 6b. In agreement with the reduction in IL-17A expression, the
frequencies and numbers of Th17 cells were significantly reduced
in the colon of IL-33-treated CR-infected mice in comparison with
Fig. 1 Influence of C. rodentium infection on colonic ST2 and IL-33 expression and IL-33 production. a C57BL/6 mice were orally gavaged
with CR on day 0. b Histopathological score of colon tissues assessed 10 days post infection. Bars represent the mean ± SEM of data from one
representative experiment (n= 3 mice per group). c Colonic mRNA expression of the membrane-bound receptor ST2 measured at the
indicated time points after infection by qRT-PCR. Bars represent fold change induction over d0 (n= 5–11 mice per group). d Serum sST2
concentrations determined on day 10 after infection via ELISA. e Il33 transcript levels (left panel) in colon biopsies and IL-33 protein secretion
from in vitro cultured colon explants (right panel) were measured via RT-PCR and Luminex technology, respectively (n= 5–6 mice per group).
f Secretion of IL-17A, TNF-α and IFN-γ from in vitro cultured colon explants determined by Luminex technology (n= 5–6 mice per group).
All data are presented as mean ± SEM and were pooled from (c) three or (d, e, f) two independent experiments. Statistical analyses were
performed using Mann–Whitney U test or Student’s t test. *P < 0.05; **P < 0.01; ***P < 0.001.
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infected controls (Fig. 6c). Colonic Th17 cells barely express ST2 at
steady-state, and ST2 expression in these cells was not induced
upon CR infection. Notably, we found increased ST2+ Th17 cell
frequencies in the colon of IL-33-treated naïve mice and, to a
lesser extent, during CR infection (Fig. 6d). Interestingly, starting
IL-33 applications by day 6 after CR infection - when Th17
differentiation is already initiated - did not alter the disease
progression, and no differences in the colonic IL-17A expression
nor in Th17 cell numbers were observed (Supplementary
Fig. 2a–e), suggesting a negative contribution of IL-33 at the early
phase of CR infection. Thus, we tested whether IL-33 may directly
affect the ability of CD4+ T cells to differentiate into Th17 cells.
Consistent with our in vivo findings, naïve CD4+ T cells showed a
reduced capacity to differentiate into Th17 cells in the presence of
IL33 in vitro (Fig. 6e). Importantly, the IL-17A expression per cell
(MFI) was not changed (Fig. 6f), indicating that IL-33 does not
affect the functional ability of differentiated Th17 cells to produce
IL-17A. Moreover, we observed neither differences in the
frequency of Foxp3+CD4+ T cells due to the presence of IL-33
(Fig. 6g) - thus excluding the possibility that IL-33 could promote
Tregs differentiation at the expense of Th17 generation - nor
alterations in the proliferative capacity of Th17-polarized CD4+
T cells (Fig. 6h). Together, these data suggest that IL-33 directly
interferes with the generation of Th17 cells early during CR
infection, which correlates with enhanced bacterial burden and
severe pathology at later stage.
IL-17A supplementation counterbalances the negative effect of
IL-33 during C. rodentium infection
To address whether IL-17A controls IL33-mediated immuno-
pathology in our model, we applied IL-17A to IL-33-treated CR-
infected mice from day 3 post infection on and characterized
disease progression (Fig. 7a). Remarkably, IL-17A supplementa-
tion prevented body weight loss and colon length shortening in
IL-33-treated infected mice (Fig. 7b, c). Furthermore, while CR-
infected mice treated with IL-33 alone exhibited severe colon
tissue damage, concomitant administration of IL33 and IL-17A
resulted in a moderate reduction of colonic immunopathology
(Fig. 7d) and a slight upregulation in Reg3γ expression (Fig. 7e).
Accordingly, systemic bacterial dissemination and serum pro-
inflammatory cytokine levels were less pronounced in IL-33+IL-
17A infected animals compared to IL-33 treated infected mice
(Fig. 7f, g).
To address the role of IL-17A specifically at the site of infection,
we generated a genetically modified CR strain expressing and
secreting IL-17A. Importantly, both wild-type (here named CR/WT)
and IL-17A-producing (CR/IL17) CR strains showed the same gut
colonization ability (Supplementary Fig. 3a). Consistent with the
data obtained from IL-17A systemic application, infection with CR/
IL17 limited the body weight loss and the systemic bacterial
dissemination consequent to IL-33 treatment (Supplementary
Fig. 3b–d). However, the constant production of IL-17A by the
infectious bacteria was not sufficient to significantly ameliorate
colon pathology (Supplementary Fig. 3e).
IL-33 impairs gut barrier integrity by directly targeting IECs
Given the substantial systemic bacterial dissemination found in IL-
33-treated CR-infected animals, we tested whether IL-33 levels
affected the integrity of the epithelial barrier in our model. First,
both non-infected and CR-infected mice were treated with IL-33,
and then orally gavaged with FITC-labeled dextran beads.
Interestingly, IL-33 treatment resulted in significantly higher FITC
concentrations in the serum, indicating enhanced gut perme-
ability, an effect that was strengthened when IL-33 was applied
Fig. 2 Lack of IL-33 or ST2 alleviates C. rodentium-induced intestinal inflammation. a Body weight changes relative to initial weight in St2−/−
and WT non-infected and CR-infected mice monitored during the course of the experiment. Statistical analyses were performed using two-way
ANOVA followed by Bonferroni’s post hoc test. b Representative pictures (scale bars 100 µm) of H&E-stained colon sections (left) and
histopathological score (right). Each parameter of colon damage and inflammation is shown as mean ± SEM. Statistical analyses were performed
using Mann–Whitney U test or Student’s t test to compare St2−/− groups with their respective WT control groups. Results from two independent
experiments are shown (n= 4–6 per group). c Body weight changes relative to initial weight in Il33−/− and WT non-infected and CR-infected mice.
Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s post hoc test. d Representative pictures (scale bars 100 µm) of
H&E-stained colon sections (left) and histopathological score (right). Middle and distal colon portions were assessed for damage and inflammation
as before. Bars show the mean ± SEM of each parameter. Statistical analysis was performed using Mann–Whitney U test or Student’s t test to
compare Il33−/− groups with their respective WT control groups (n= 3 mice per group). *P < 0.05; **P < 0.01; ***P < 0.001.
Interleukin-33 signaling exacerbates experimental infectious colitis by. . .
V Palmieri et al.
4
Mucosal Immunology _#####################_
Fig. 3 Detrimental effect of IL-33 administration during C. rodentium infection. a C57BL/6 mice were orally gavaged with CR on day 0.
Non-infected and CR-infected mice received IL-33 or PBS (control groups) intraperitoneally on day 0, 2, 4, and 6 after infection. Mice were
sacrificed before the body weight loss exceeded 20%. b Body weight was monitored daily during infection (n= 18–23 mice per group).
Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s post hoc test. c Bacterial load in feces assessed at the
indicated time points after infection (n= 22–23 mice per group). Statistical analyses were performed using Mann–Whitney U test to
compare groups at each time point. d Macroscopic score of colitis based on shortening of colon length (n= 18–23 mice per group). One-
way ANOVA followed by Tukey’s multiple comparison test was used for statistical analysis. All data are presented as mean ± SEM and were
pooled from seven independent experiments. e Representative pictures (scale bars 100 µm) of H&E-stained colon sections (left) and
histopathological score (right). Bars show the mean ± SEM of each inflammatory parameter analyzed. Data from three independent
experiments are shown (n= 8–10 mice per group). Statistical analyses were performed using Student’s t test to compare IL-33-treated
groups with non-treated groups, respectively with or without infection. f Colonic Reg3g mRNA expression determined by qRT-PCR. Bars
show the mean ± SEM of fold change induction over non-infected, non-treated group. One-way ANOVA followed by Tukey’s multiple
comparison test was used for statistical analysis. Results from three experiments are shown. g Systemic bacterial distribution was assessed
by plating whole blood and serial dilutions of homogenized tissues on MacConkey agar. Bars represent the mean ± SEM of data from three
experiments. h In the same experiments, serum levels of inflammatory cytokines were measured via Luminex technology. Bars indicate
the mean ± SEM of cytokine picograms per milliliters of serum (n= 11–12 mice per group). Statistical analysis was performed using
Mann–Whitney U test. *P < 0.05; **P < 0.01; ***P < 0.001.
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during infection (Fig. 8a). Moreover, IL-33-treated animals showed
substantial defects in the expression of occludin (Ocln) and, to a
lesser extent, of tight junction protein 1 (Tjp1) within the colon
(Fig. 8b). Well in line, the genetic ablation of IL-33 during CR
infection resulted in enhanced expression of tight junction-
related proteins (Supplementary Fig. 4a). Thus, we next analyzed
whether an active inhibition of endogenous IL-33 signaling
during CR infection using a ST2 blocking antibody (ST2-Ab)
confers protection to the intestinal epithelium (Fig. 8c). Similar
to our findings in St2−/− mice, ST2-Ab treated CR-infected mice
exhibited moderate less body weight loss and colon damage
compared to infected animals receiving the isotype control
(Fig. 8d and Supplementary Fig. 5). More importantly, colonic
expression of both Ocln and Tjp1 was significantly higher in
these mice (Fig. 8e), pointing out the detrimental role of IL-33/
ST2 signaling on gut epithelium integrity during CR infection. To
verify that IL-33 directly targets IECs and does not exert its
effects indirectly via other immune cells or cytokines, we made
use of murine intestinal epithelial MODE-K cell lines, which
upregulate ST2 expression upon IL-33 treatment (Supplemen-
tary Fig. 4b). Notably, transcript levels of both Ocln and Tjp1
were significantly reduced when cells were treated with IL-33
(Supplementary Fig. 4c), thus indicating a direct effect of IL-33
on gut epithelial cells.
IL-17A counteracts the negative effect of IL-33 on gut permeability
Inhibition of IL-17A signaling has been associated with impair-
ment of the intestinal epithelial barrier and exacerbated colitis21.
As we observed a negative effect of IL-33 on the gut barrier
integrity during CR infection and that IL-17A supplementation
limited the otherwise strong systemic spreading of the patho-
gen induced by IL-33, we combined the treatment with both
cytokines in vivo under homeostasis and during CR infection,
and assessed the intestinal permeability. Remarkably, IL-17A
supplementation attenuated the enhanced gut permeability
induced by IL-33 (Fig. 9).
We therefore conclude that IL-33 application impairs the integrity
of the gut epithelium, which enhances the bacterial translocation
from the intestinal lumen to systemic sites. Concomitantly, IL-33
inhibits the differentiation of IL-17A-producing CD4+ T cells, which
have the potential to reverse the negative effect of IL-33 during
infection. Taken together, our findings demonstrate that the balance
between IL-17A and IL-33 levels is critical for the control of CR-
mediated intestinal immunopathology.
DISCUSSION
The intestinal epithelium represents one of the first lines of
defense against invading pathogens22. Alteration in the epithe-
lium structure and barrier integrity are detrimental to the
organism. CR is a non-invasive pathogen, and the infection is
normally limited to the distal part of the colon17. Importantly, we
observed a severe bacterial dissemination into the peripheral
system with enhanced systemic inflammatory cytokine production
in mice infected with CR and concomitantly treated with IL-33.
Well in line with a study by Sedhom and colleagues23, our results
demonstrated that IL-33 directly inhibits the expression of tight
junction-related proteins in vitro and in vivo. Furthermore, IL-33
treatment strongly enhanced the intestinal permeability in vivo,
thereby favoring bacterial translocation that amplifies systemic
and colonic inflammation. Following CR infection, the upregula-
tion of the antimicrobial peptide REG3γ in the colon was impaired
by concomitant IL-33 application. Consequently, IL-33-treated CR-
infected animals displayed elevated intestinal CR burdens. Xiao
and colleagues recently showed that the steady-state expression
of REG3γ in IECs of Il33−/− mice is lower than in WT mice24.
Of note, IL-33-deficient mice have been reported to be dysbiotic,
or have a higher concentration of pro-inflammatory bacteria
Fig. 4 ST2-expressing Treg cells preferentially infiltrate the colonic lamina propria in response to C. rodentium infection. Immune cell
subsets isolated from the colonic lamina propria of non-infected and CR-infected mice were analyzed by flow cytometry. Frequencies (a) and
absolute numbers (b) of ST2+ cells were measured among F4/80+CD11b+ macrophages (Mph), Ly6G+CD11b+ neutrophils (Nph),
CD11c+CD11b-F4/80- dendritic cells (DCs), Lin-CD127+ innate lymphoid cells (ILCs), CD8+ T cells, CD4+ T cells, and among Foxp3+CD4+ T cells
(Tregs) and Foxp3-CD4+ T cells. Data from one experiment are shown as mean ± SEM (n= 3-4 mice per group). Statistical analyses were
performed using Mann–Whitney U test to compare each infected group with the respective non-infected control group. *P < 0.05; **P < 0.01;
***P < 0.001.
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compared to WT mice25. Thus, the basal expression of REG3γ in
Il33−/− mice may be altered due to the complex interaction
between intestinal epithelium, immune system and microbiota.
Intriguingly, the authors showed that the in vitro treatment of
intestinal epithelial cell lines with IL-33 induced the expression of
REG3γ24. Yet it is not clear how these data compare with our, as
the authors focused on IL-33 and REG3γ at steady-state, in cell
culture conditions, and at the late phase of CR infection when the
Fig. 5 Effect of Treg-specific ST2 ablation on C. rodentium-induced colitis upon IL-33 treatment. a Mice were treated as described in
Fig. 3a. Colonic frequencies of Foxp3+ cells (Tregs) among CD4+ T cells (left) and of ST2+ (middle) or ST2− cells (right) among Tregs
determined by flow cytometry. Bars indicate the mean±SEM of data from two independent experiments (n= 6–7 mice per group). Statistics
were performed using one-way ANOVA followed by Tukey’s multiple comparison test. b Schematic illustration of IL-33 treatment during CR
infection in ST2fl/fl/FIC transgenic mice and control FIC littermates. Colonic Treg-specific ST2 ablation was confirmed via flow cytometry. Each
bar shows the mean±SEM of 4 mice. Statistical significances were calculated using Mann–Whitney U test. c Body weight changes represented
as percentage of initial weight on day 0. Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s post hoc test.
d Macroscopic score of colitis based on colon length shortening. e Representative pictures (scale bars 100 µm) of H&E-stained colon sections
(left) and histopathological score (right). Bars show the mean ± SEM of each parameter analyzed. f Systemic bacterial distribution assessed by
plating serial dilutions of homogenized livers and spleens on MacConkey agar. Dot plots and the mean ± SEM of CFU per grams of tissue are
shown. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test or Kruskal-Wallis ANOVA with
Dunn’s multiple comparison test. All the data shown derive from two independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
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Fig. 6 IL-33 interferes with the differentiation of IL-17A-producing Th17 cells. Mice were treated as described in Fig. 3a. a qRT-PCR analysis
of Il17a mRNA expression in colon biopsies from non-infected and CR-infected WTmice treated or not with IL-33. Data from two independent
experiments are shown as mean ± SEM of fold change induction over non-infected, PBS-treated group. b Flow cytometry dot plots of one
representative infected colon showing the gating strategy applied to assess the proportion of IL-17A+ cells among Foxp3-CD4+ T cells (right
panel) within the colonic lamina propria. c Frequencies and absolute numbers of IL-17A+ cells were measured among Foxp3-CD4+ T cells.
d Percentage of ST2+ cells among Th17 cells. Bars represent the mean ± SEM of data from three independent experiments (n= 9–12 mice per
group). All statistical analyses were performed using one-way ANOVA followed by Tukey’s multiple comparison test or Kruskal-Wallis ANOVA
with Dunn’s multiple comparison test. e Sort-purified splenic CD4+CD25- T cells were cultured for 5 days under Th17-polarizing conditions in
presence or absence of IL-33. On day 5, cells were counted and stained for FACS analysis. The same gating strategy applied to colonic LPLs
and shown in panel b was used in this particular dataset to measure the percentage and absolute numbers of IL-17A-expressing cells among
Foxp3-CD4 T cells (e), and to assess their mean fluorescent intensity (MFI) for IL-17A (f). In the same experiments, the percentage of Foxp3+
cells among CD4+ T cells was evaluated (g). Data from two independent experiments are shown (n= 6 mice). h Sort-purified CD4+CD25-
T cells were labeled with the proliferation dye eFluor 670 and cultured for 5 days under Th17-polarizing conditions with or without IL-33.
Proliferation was determined as loss of eFluor 670 by flow cytometry. Representative histogram-overlay is illustrated. Bars indicate the mean ±
SEM of n= 2 mice. Statistical analyses were performed using Paired t test. *P < 0.05; **P < 0.01; ***P < 0.001.
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bacteria are almost cleared in WT mice. In our study, we
concentrated on pathological aspects of acute CR infection within
the colon of mice with impaired IL-33/ST2 signaling. In addition,
we addressed the effect of exogenous IL-33 application on REG3γ
expression in vivo during acute CR infection.
The balance between Tregs and Th17 cells is an important
regulator of inflammation within the gut26. Interestingly, IL-33 is
suggested to influence both Tregs and Th17 cells. ST2 is highly
expressed on colonic Tregs at steady-state, and IL-33 was shown
to increase their expression of ST2 and Foxp3 as well as to
promote their suppressive function27. During CR-mediated colitis,
Tregs protect the host against excessive immunity, but may also
increase the risk of pathogen persistence and chronic disease.
Wang et al. demonstrated that depletion of Tregs during the
Fig. 7 IL-17A supplementation during infection compensates the detrimental effect of IL-33. a CR-infected mice were treated with PBS
(control group) or IL-33 as in Fig. 3a. Starting by day 3, one group of CR-infected IL-33-treated mice and one group of CR-infected non-treated
mice received IL-17A daily until the end of the experiment. b Body weight changes during the course of infection are presented as percentage
of initial weight on day 0. Statistical analyses were performed by two-way ANOVA followed by Bonferroni’s post hoc test. c Macroscopic score
of colitis was assessed based on shortening of colon length. d Representative pictures (scale bars 100 µm) of H&E-stained colon sections (left)
and histopathological score (right). e Reg3g mRNA expression in colon biopsies was determined by qRT-PCR and shown as fold change
induction over PBS-treated group. f Systemic bacterial distribution upon IL-33 and/or IL-17A treatment was assessed on day 8 after infection in
homogenized livers and spleens. g Serum cytokine levels were measured via Luminex technology. All data are presented as mean ± SEM and
were pooled from two independent experiments (4–6 mice per group). Statistical analyses were performed using one-way ANOVA followed
by Tukey’s multiple comparison test or Kruskal-Wallis test. *P < 0.05; **P < 0.01; ***P < 0.001.
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Fig. 8 IL-33 impairs intestinal epithelial barrier integrity. a Mice were treated with IL-33 or PBS every 2 days for 1 week in presence or
absence of concomitant CR infection. On day 7, mice received FITC-dextran beads via oral gavage. Serum FITC concentrations were
measured 4h after gavage. Bars indicate the mean±SEM of FITC-dextran micrograms per milliliters of serum. b Colonic mRNA expression
of the tight junction-related proteins Ocln (left) and Tjp1 (right) determined via qRT-PCR. Graphs show dot plots and mean±SEM of fold
change induction over PBS-treated groups. Results from three (non-infected, n= 10 mice per group) and two (CR-infected, n= 6 mice per
group) independent experiments are shown. Statistical analyses were performed using Mann–Whitney U test or Student´s t test
to compare IL-33-treated groups with their respective PBS-treated groups. c C57BL/6 mice were infected with CR and were treated with
ST2-blocking antibody (ST2-Ab) or isotype antibody (Iso-Ab, control group) starting by day 3 after infection. d Histopathological analysis
of colonic tissues based on the scoring system described in “Methods”. e Colonic mRNA expression of Ocln and Tjp1 was assessed via qRT-
PCR. Dot plots indicate fold change induction over Iso-Ab treated group. Statistical analysis was performed using Student’s t test. All data
are presented as mean±SEM and were pooled from two independent experiments (n= 6 mice per group). Statistical analysis was
performed using Mann–Whitney U test or Student’s t test to compare the ST2-Ab-treated group with the Iso-Ab control group. *P < 0.05;
**P < 0.01; ***P < 0.001.
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course of CR infection impairs bacterial clearance and the
induction of a protective Th17 response28. In our model, IL-33
treatment of infected mice strongly increased the frequency of
colonic Tregs; however, excessive inflammation in the colon was
detected. In line with this finding, the depletion of Foxp3+Tregs in
CR-infected mice treated with IL-33 did not rescue the phenotype
and ameliorate the pathology, suggesting that the deleterious
effects elicited by IL-33 are not dependent on the expansion of
Tregs in our model. However, we cannot exclude that the
expansion of ST2+Foxp3+ Tregs has some benefits for the host
during CR infection, as mice with Treg-specific ST2 depletion
showed slightly increased colon pathology compared to animals
with ST2-sufficient Tregs.
CR infection elicits a strong Th17 response in the colon29.
Through the production of IL-22 and IL-17, Th17 cells provide
signals for the secretion of antimicrobial peptides within the
intestinal epithelium30. Consequently, mice lacking IL-17A showed
an impaired ß-defensin production in infected colons accompa-
nied by increased CR burden20. Remarkably, our results show that
IL-33 treatment during CR infection reduced the frequencies of
IL-17A-expressing CD4+ T cells within the infected colon, and
the impaired IL-17A response correlated with the uncontrolled
pathogen clearance. Moreover, IL-33 directly inhibited the
differentiation of Th17 cells in vitro. As ST2 expression by Th17
cells is very low at baseline, IL-33 should not impair the production
of IL-17A in already in vitro polarized Th17 cells. This may explain
why IL-33 treatment in the later phase of infection, when the
differentiation of Th17 cells already has taken place, does not
appear to affect CR-mediated immunopathology. Our findings
raise the question whether the host may have a benefit from IL-
33/ST2 deficiency or whether local IL-17A supplementation boosts
host defense mechanisms against extracellular bacteria. Indeed,
we observed that the re-establishment of IL-17A levels counter-
acts the strong systemic microbial dissemination elicited by IL-33
treatment during CR infection. IL-17A was suggested to be
involved in preserving gut barrier functions. Lee et al. demon-
strated that the genetic ablation or antibody neutralization of IL-
17A signaling increased gut permeability in both chemically- and
T cell transfer-induced colitis31. Moreover, IL-17A and IL-17RA
inhibition have been associated with the breakdown of the
intestinal epithelial barrier and exacerbated colitis in Helicobacter
bilis-infected mice21. Here, we demonstrated that exogenous IL-
17A supplementation abrogates the negative effect of IL-33 on
the intestinal permeability. Nevertheless, administration of IL-17A
during CR infection was not sufficient to rescue the severe
immunopathology. This could be due to the fact that Th17 cells
not only produce IL-17A but also IL-223. In acute colonic infections,
such as CR, where rapid repair of colonic epithelial cells is
required, IL-22 plays a protective role by facilitating epithelium
restoration and by enhancing IEC-derived antimicrobial pep-
tides32. Interestingly, supplementation of IL-33-treated CR-infected
mice with exogenous IL-22 neither ameliorated colon pathology
nor rescued the downregulation of Reg3g expression induced by
IL-33 treatment (data not shown). Thus, an impaired IL-22
signaling does not account for the pathogenic potential of IL-33
in our infectious model.
IL-33 is frequently described to promote type-2 immunity by
inducing ILC2s and Th2 cells5,8, which could inhibit an effective
Th1/Th17 response. Notably, colonic type-2 cytokine levels and
the frequency of ILC2 cells were increased in IL-33 treated non-
infected mice (Supplementary Fig. 6a, b). However, in IL-33 treated
CR-infected mice these enhanced type-2 responses were almost
abolished, probably due to a counteracting Th1 cytokine response
and higher frequencies of IL-17 producing ILC3 cells induced by
CR33. Nonetheless, IL-33 treatment during CR infection induced a
low percentage of ILC2 to the detriment of ILC3 (Supplementary
Fig. 6b), which may affect the subsequent development of an
efficient adaptive immune response. Thus, we cannot completely
exclude that a misbalance between ILC2s and ILC3s might also
contribute to the reduced Th17 response during CR infection.
In the present study, we found that IL-33 levels in the colon
were only slightly increased following CR infection, but the
expression of the IL-33-receptor ST2 was significantly enhanced in
the colon of CR-infected mice. Similar expression profiles were
observed in patients suffering from enterohemorrhagic E. coli
(EHEC)-driven hemolytic uremic syndrome (HUS)34. Whereas IL-33
serum levels in HUS patients were not altered compared to
healthy controls, the serum levels of sST2 were significantly
increased in the HUS phase and correlated with disease severity34.
However, the functional impact of IL-33/ST2 pathway on EHEC
infections is still unrevealed.
IL-33 and IL-17A have been separately described to play
dichotomous functions in the gut depending on the infection
context. Colonization with the pathobiont adherent-invasive E. coli
(AIEC) was shown to potentiate the expression of IL-33 and ST2 in
the intestine mediated by the bacterial flagellin35. Furthermore,
AIEC colonization of Il17−/− mice resulted in increased intestinal
epithelial damage, systemic bacterial dissemination and mortality,
indicating that IL-17 plays a protective role in AIEC-induced
colitis36. Thus, we suggest that the flagellin-driven expansion of
ST2 and IL-33 could be a self-protective mechanism of AIEC to
counterbalance the induction of Th17-mediated responses.
Fig. 9 IL-17A counteracts the enhanced gut permeability induced by IL-33. Naïve and CR-infected mice were treated with IL-33 or PBS on
day 0, 2, 4, and 6. Starting by day 3, one group of IL-33-treated mice and one group of non-treated mice received IL-17A daily. On day 7, serum
FITC concentrations were measured after FITC-dextran oral gavage. Bars represent the mean ± SEM of FITC-dextran micrograms per milliliters
of serum. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test (non-infected, n= 4 mice per
group, CR-infected, n= 6-7 mice per group). *P < 0.05; **P < 0.01; ***P < 0.001.
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In contrast, IL-33 signaling was described to be critical for
intestinal protection during Clostridium (C.) difficile colitis. Frisbee
and colleagues demonstrated that colonic IL-33 was amplified in
response to mouse and human C. difficile infection, and a
dysregulation of IL-33 signaling was associated with higher
patient mortality37. Interestingly, in humans, Th17 cytokines in
the serum are associated with severe C. difficile infection, and
adoptive transfer of Th17 cells to C. difficile-infected mice
increased mortality38. In this setting, enhanced colonic IL-33
expression during C. difficile infection could protect the host by
inhibiting the differentiation of Th17 cells. Taken together, these
and our data indicate that IL-33 and IL-17A adversely regulate
the host response during infection with different intestinal
bacteria.
Based on our results, it is tempting to speculate about a
temporal hierarchy of IL-33/IL-17A effects in the host response to
gut pathogens. IL-33 is highly abundant in the intestine at steady-
state, and the expression of IL-33 or ST2 enhances upon tissue
damage. In contrast, Th17 cells belong to the adaptive immune
response that starts in a later phase of infection. Since IL-33
treatment does not impair the immune response in the late phase
of CR infection, it is likely that IL-17A has the power to
counterbalance the early pathogenic potential of IL-33 within
the gut. However, additional experiments are needed to better
characterize the reciprocal regulation of intestinal IL-33 and IL-17A
levels during the course of bacterial infection.
In summary, our findings extend the broad spectrum of
functions of IL-33, and highlight the special role of the gut as an
organ with systemic immune-regulatory properties. Exploring the
crucial and diverse roles of the IL-33/ST2 axis during infections
may help in the development of therapeutic interventions for a
range of intestinal infectious diseases.
METHODS
Mice
All animal experiments at the University Hospital Essen were
performed in accordance with ethical principles and federal
guidelines, and approved by the local authority Landesamt für
Natur, Umwelt und Verbraucherschutz (LANUV, North-Rhine
Westphalia, Germany). C57BL/6 J WT mice (6–8 week old females)
were purchased from Envigo (Horst, Netherlands). DEREG
transgenic mice were established as previously described39, and
bred in-house. ST2fl/fl/FIC mice were generated by crossing
Il1rl1tm1c(KOMP)Wtsi (www.komp.org)40 with Foxp3tm1(cre)Saka mice41.
All animal experiments at the University of Bern were
performed in agreement with Swiss Federal regulations and
were approved by the Cantonal Veterinary Office of Bern,
Switzerland. Il1rl1tm1Anjm (St2−/−) mice were previously
described42, and backcrossed on a C57BL/6 J background.
Il33−/− mice were obtained through the RIKEN Center for
Developmental Biology (http://www.cdb.riken.jp/arg/mutant%
20mice%20list.html)43, and bred in-house. For all experiments,
mice were either co-housed (for females), or soiled bedding was
exchanged weekly (for males).
Bacterial strains and infection of mice
Bacterial-driven colitis was induced in mice by oral inoculation
with ~2 × 109 colony forming units (CFU) of WT CR strain ICC169,
as previously described44. In some studies, a genetically modified
CR strain was used, which constitutively secretes IL-17A (named
CR/IL-17) (see Supplementary methods for construct details).
In vivo treatments
Recombinant mIL-33 (1 µg/mouse, BioLegend) was administered i.
p. to the mice immediately upon infection on day 0 and every two
days for the duration of the experiment. Where indicated,
recombinant mIL-17A (1 µg/mouse, BioLegend) was supplemen-
ted i.p. daily, starting by day 3 after infection. As late treatment, IL-
33 was administered every two days starting by day 6 after
infection. For pharmacological inhibition of endogenous IL-33/
ST2 signaling, a blocking antibody against ST2 (20 µg/mouse, R&D
Systems) was supplemented i.p. every two days starting by day 3
post infection.
Histopathological analysis
Full-length colons were stored in 4% paraformaldehyde and
embedded in paraffin. Sections (4 μm) were prepared from
paraffin-embedded blocks, stained with hematoxylin and eosin
(H&E) and evaluated in a blinded manner, according to standard
techniques as described previously45. In brief, middle and distal
colon portions were assessed for damage and inflammation (each
parameter analyzed was scored 0= none; 1=mild; 2=moderate;
3= severe change).
Protein quantification
sST2 concentrations in serum were measured using a commer-
cially available enzyme-linked immunosorbent assay (ELISA) kit for
murine sST2 (ThermoFisher). Cytokine levels in the serum were
quantified using polystyrene bead-based Luminex technology
(R&D Systems). Quantification of cytokines secreted in the
supernatants of 6-hour in vitro cultured colonic explants was
performed as previously described46, using a Luminex 200 system
(Luminex Corporation).
Isolation of colonic lamina propria lymphocytes
Lamina propria lymphocytes (LPLs) were isolated from the colon
as described in Supplementary methods.
In vitro Th17 cell differentiation and proliferation assay
Naïve CD4+ T cells were isolated from the spleens of C57BL/6
mice using the CD4+ T Cell Isolation Kit II (Miltenyi Biotec). CD4+
CD25- T cells were sorted using a FACSAria II cell sorter
(BD Biosciences). Purified cells were cultured for 5 days with
plate-bound anti-CD3 (clone 145–2C11) (1 μg/mL) and soluble
anti-CD28 (clone 37.51) (1 μg/mL) (both BD Bioscience). To
induce Th17 differentiation, culture medium was supplemented
with recombinant TGFβ (2 ng/mL), IL-21 (100 ng/mL), IL-23
(20 ng/mL), IL-6 (50 ng/mL), IL-1β (20 ng/mL), and blocking
antibodies for IL-4 (200 ng/mL), IFN-γ (200 ng/mL), and IL-2
(200 ng/mL), respectively. Where indicated, rmIL-33 (10 ng/mL)
(BioLegend) was added to the culture. On day 5, cells were
counted, stained and analyzed by flow cytometry as described
below. To assess cell proliferation, sorted-purified CD4+ CD25-
T cells were labeled with the cell proliferation dye eFluor 670
(eBioscience) following the manufacturer’s instructions prior to
5-day stimulation with or without IL-33 under Th17 cell-skewing
conditions. Loss of eFluor 670 was assessed by flow cytometry as
indicative of cell proliferation.
Antibodies and flow cytometry
Cells were incubated with marker-specific fluorochrome-labeled
anti-mouse antibodies listed in Supplementary Table 2 and
described in Supplementary methods. Cells were analyzed by
flow cytometry on a LSR II instrument using DIVA software (BD
Biosciences).
FITC-dextran intestinal permeability assay
Mice were orally gavaged with 150 μl of 100 mg/mL 4 kDa FITC-
dextran-labeled dextran beads (Sigma-Aldrich) in PBS 4 h prior to
sacrifice. FITC-derived fluorescence was quantified in the serum
using a microplate luminometer (Mithras LB 943; Berthold).
Concentrations were determined using a standard curve gener-
ated by serial dilution of FITC-dextran.
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RNA extraction and quantitative RT-PCR
RNA was isolated from colon biopsies as described before47.
Primer sequences are listed in Supplementary Table 1. Relative
mRNA levels were determined based on the standard curves for
each individual gene and normalized to the expression of the
housekeeping gene ribosomal protein S9 (RPS9).
Statistical analysis
All analyses were performed using the Prism 7.03 software
(GraphPad, La Jolla, CA). Unless specified, only statistically
significant differences are indicated in the figures. *P < 0.05;
**P < 0.01; ***P < 0.001.
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